June 5, 2019
Pillet S et al. PLoS One 2019;14(6):e0216533.
Immunogenicity and Safety of a Quadrivalent Plant-derived Virus Like Particle Influenza Vaccine Candidate – Two Randomized Phase II Clinical Trials in 18 to 49 and ≥50 Years Old Adults
You might also be interested by
CellTalk Blog
ELISpot vs. ICS: Optimizing Immune Monitoring in Clinical Trials with the Right Functional Assay
November 19, 2024
Immune Monitoring
More infoCellTalk Blog
Measure Target Engagement With Receptor Occupancy Assays by Flow Cytometry
September 17, 2024
Immune Monitoring
More infoBrochures & Infographics
High Performance Technologies for Cytokine Measurement
July 29, 2024
Immune Monitoring
More info